An open-label, single-arm, phase 2 study explored the effects of paltusotine in patients with acromegaly who switched from SRL depot injections and showed that IGF-I and GH levels were maintained and patient-reported symptom burden remained stable (18). This evidence concerns the gene IGF1 and acromegaly.